Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

EVOK stock opened at $4.70 on Wednesday. The stock’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.49. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.40. The company has a market cap of $7.00 million, a P/E ratio of -0.43 and a beta of 0.36.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the SEC.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.